公开(公告)号：EP4357364A1

公开(公告)日：2024-04-24

申请号：EP22914112.2

申请日：2022-12-07

申请人： Hefei TG Immunopharma Co., Ltd.

发明人： TIAN, Zhigang ,  CAO, Guoshuai ,  XIAO, Weihua ,  SUN, Rui ,  SUN, Haoyu

IPC分类号： C07K16/28 ,  G01N33/574 ,  C12N15/13 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P31/00

摘要： Disclosed is an antibody and use thereof. The antibody or antigen binding fragment includes CDR sequences selected from at least one of heavy-chain variable region CDR sequences: SEQ ID NOs: 1-3; and light-chain variable region CDR sequences: SEQ ID NOs: 4-6. The antibody prepared by the present disclosure can effectively bind to the α3 domain of MICA or MICB, and further, promote the binding of NKG2D to MICA and/or MICB, and can effectively treat or prevent related diseases mediated by MICA and/or MICB, such as promoting the killing of tumors by NK cell.

公开(公告)号：EP4353748A1

公开(公告)日：2024-04-17

申请号：EP22819527.7

申请日：2022-06-07

申请人： SHANGHAI SYNVIDA BIOTECHNOLOGY CO. LTD.

发明人： LIU, Junling ,  FAN, Xuemei ,  SUN, Tianyao

IPC分类号： C07K16/36 ,  C12N15/13 ,  A61K39/395 ,  A61P7/02

CPC分类号： A61K39/395 ,  A61K47/65 ,  A61K47/68 ,  A61K47/64 ,  A61P7/02 ,  C07K16/00 ,  C07K16/36 ,  C07K19/00

摘要： The present invention provides a novel antithrombotic antibody, the antibody uses FIXa as a target and has unique properties, and specifically targets the binding site of coagulation factor FIXa and FVIIIa, reduces the formation of a FVIIa-FIXa complex, blocks the conversion of FX to FXa, and thereby exerts an antithrombotic effect. The antibody of the present invention has suitable antithrombotic properties, and has a large effective therapeutic concentration window, but does not increase the risk of bleeding in addition, the antibody can meet the needs for suitable antithrombotic performance in clinical application and for effective avoidance of problems regarding bleeding caused by excessive effects. The present invention also discloses a method for screening drugs by using an FIXa-FVIIIa binding site as a target.

公开(公告)号：EP4347664A1

公开(公告)日：2024-04-10

申请号：EP22815201.3

申请日：2022-05-30

申请人： Shijiazhuang Yiling Pharmaceutical Co., Ltd.

发明人： JIA, Zhenhua

IPC分类号： C07K16/46 ,  C12N15/13 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00

公开(公告)号：EP4347646A1

公开(公告)日：2024-04-10

申请号：EP21943534.4

申请日：2021-06-02

申请人： Huahui Health Ltd.

发明人： SUI, Jianhua ,  TIAN, Xinxin

IPC分类号： C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  A61K39/395 ,  A61P35/00

公开(公告)号：EP4342989A1

公开(公告)日：2024-03-27

申请号：EP22804768.4

申请日：2022-05-20

申请人： Denka Company Limited

发明人： SAITO, Yuji ,  HIRAOKA, Koji ,  OGASAWARA, Shinya

IPC分类号： C12N15/13 ,  C07K16/10 ,  C12M1/34 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/63 ,  C12P21/08 ,  C12Q1/02 ,  G01N33/569

摘要： Disclosed is an anti-norovirus antibody that reacts with noroviruses of many genotypes and can collectively detect the noroviruses. The anti-norovirus antibody or an antigen-binding fragment thereof undergoes antigen-antibody reaction with the peptides composed of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The anti-norovirus antibody, which can broadly bind to noroviruses and detect a wide range of human noroviruses with high specificity and sensitivity, and a norovirus immunoassay and a norovirus immunoassay device, both using the anti-norovirus antibody, are provided.

公开(公告)号：EP4342913A1

公开(公告)日：2024-03-27

申请号：EP22804030.9

申请日：2022-05-19

申请人： Shanghai Escugen Biotechnology Co., Ltd. ,  Guangzhou Yinnuolai Biotechnology Co., Ltd.

发明人： ZHANG, Xinmin ,  NIAN, Weihong ,  XU, Chuanying ,  HE, Feng ,  ZHOU, Qing ,  ZHANG, Jianbing

IPC分类号： C07K16/24 ,  C12N5/10 ,  C12N15/13 ,  A61K35/17 ,  A61P35/00

摘要： The present application discloses a chimeric antigen receptor molecule for specifically recognizing BAFF-R, a nucleic acid encoding the receptor molecule, an engineered immune effector cell comprising the receptor molecule, a pharmaceutical composition, and a use thereof. The receptor molecule comprises a structural domain that specifically recognizes the BAFF-R and an activation stimulation structural domain, and can activate a downstream signal path after specifically recognizing and binding the BAFF-R, thereby causing, promoting or improving an immune response reaction for the BAFF-R, and finally achieving the purpose of treating or preventing diseases caused by B cell BAFF-BAFF-R signal path imbalance.

公开(公告)号：EP4339206A1

公开(公告)日：2024-03-20

申请号：EP22906548.7

申请日：2022-12-13

申请人： Ningbo Sansheng Biological Technology Co., Ltd.

发明人： ZHANG, Yong ,  ZHENG, Xingchang ,  WANG, Aike ,  JIN, Jiamin ,  YANG, Jiale ,  SUN, Di ,  CHEN, Yu ,  YANG, Junshuai ,  CHEN, Yong ,  CHEN, Lu ,  ZHOU, Sichao

IPC分类号： C07K16/26 ,  C12N15/13

摘要： The present disclosure provides an anti-inhibin antibody and its applications. The antibody can have the inhibitory effect of inhibins on the secretion of endogenous follicle-stimulating hormone (FSH), promote the secretion of endogenous FSH and promote the development of animal follicles. The antiobidy can replace the use of FSH or pregnant mare serum Gonadotropin (PMSG) in animal reproduction, and can be used for promoting animal reproduction, estrus synchronization, conception and birth, embryo transferring, improving ovulation quality, promoting livestock reproduction, inducing estrus in female livestock.

公开(公告)号：EP4337702A1

公开(公告)日：2024-03-20

申请号：EP22806836.7

申请日：2022-05-12

申请人： Wuxi Biologics Ireland Limited

发明人： SHEN, Yuhong ,  LI, Jie ,  LI, Jing

IPC分类号： C07K16/46 ,  C07K16/28 ,  C12N15/13 ,  A61K39/395 ,  A61P35/00

公开(公告)号：EP4327823A1

公开(公告)日：2024-02-28

申请号：EP22791768.9

申请日：2022-04-21

申请人： Astellas Pharma Inc. ,  National Cancer Center

发明人： TENDA, Yoshiyuki ,  YURI, Masatoshi ,  YAGI, Shigenori ,  SATAKE, Yoshiki ,  HIRAYAMA, Kazunori ,  SHIRAI, Hiroki ,  SASAKI, Hiroki ,  CHIWAKI, Fumiko ,  KOMATSU, Masayuki

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/46 ,  C12N5/10 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N15/13 ,  C12N15/62 ,  C12N15/63 ,  C12P21/08

摘要： An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.
An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD 137 antibody binding to CD137 had agonistic activity for CD 137, promoted production of interferon y by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.

公开(公告)号：EP4317439A1

公开(公告)日：2024-02-07

申请号：EP22781256.7

申请日：2022-03-31

申请人： Shionogi & Co., Ltd ,  OSAKA UNIVERSITY

发明人： YOSHIDA, Tetsuya ,  YOSHIKAWA, Mai ,  HARUNA, Miya ,  NAGIRA, Morio ,  TAKAHASHI, Koji ,  HAYASHIDA, Marina ,  MIWA, Hiroto ,  SONODA, Yudai ,  OHKURA, Naganari ,  SAKAGUCHI, Shimon ,  WADA, Hisashi

IPC分类号： C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K19/00 ,  C12N5/10 ,  C12N15/12 ,  C12N15/13 ,  C12N15/63

摘要： The chimeric antigen receptor that recognizes CCR8 as an antigen of the present invention has cytotoxic activity against CCR8-expressing cells by being expressed in effector cells.